StockCIK 1157601

MADRIGAL PHARMACEUTICALS, INC. (MDGL): Insider Trades and Fund Holdings

In the past 12 months, MADRIGAL PHARMACEUTICALS, INC. insiders reported 0 open-market purchases worth $0 and 3 sales worth $6.58M; 2 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months

$0Bought by insiders, 12 months

$6.58MSold by insiders, 12 months

1Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 11, 2026.

Recent MDGL insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Sep 11	Sep 9	William John SiboldCEO	CEO	▼ SELL10b5-1	6,362	535.59	$3.41M	−3.0%	Form 4 ↗
Sep 11	Sep 11	William John SiboldCEO	CEO	▼ SELL10b5-1	5,221	542.39	$2.83M	−2.6%	Form 4 ↗
Aug 20	Aug 17	Shannon T. KelleyGeneral Counsel	General Counsel	▼ SELL	664	514.97	$342K	−5.5%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Buys	Bought	Sells	Sold	Latest
William John Sibold	CEO	0	$0	2	$6.24M	Sep 11, 2026
Shannon T. Kelley	General Counsel	0	$0	1	$342K	Aug 20, 2026

Tracked funds that report MDGL

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Renaissance Technologies	Q2 2026	45,942	$24.7M	0.03%	▼ −36.1%
Bridgewater Associates	Q2 2026	0	$0	0.00%	▼ Sold out

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →